DexCom Announces Upcoming Conference Presentations

SAN DIEGO--()--DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on DexCom at the following upcoming investor conferences:

  • Steven Pacelli, Executive Vice President, Strategy and Corporate Development, will present an update on the company at the Canaccord Genuity Growth Conference in Boston, MA on Wednesday, August 10, 2016 at 11:00am (EST). The presentation, which will occur live at the Intercontinental Hotel, will be concurrently webcast.
  • Jess Roper, Senior Vice President and Chief Financial Officer and Matthew Dolan, Senior Director Corporate Affairs, will present an update on the company at the 2016 Wedbush PacGrow Healthcare Conference in New York City, NY on Tuesday, August 16, 2016 at 1:20pm (EST). The presentation, which will occur live at the Le Parker Meridien Hotel, will be concurrently webcast.

The link to the webcast will be available on the DexCom website at www.dexcom.com by navigating to “Our Company,” then “Investor Relations,” and finally “Events and Webcasts” and will be archived there for future reference.

About DexCom, Inc.

DexCom, Inc., headquartered in San Diego, California, is developing and marketing continuous glucose monitoring systems for ambulatory use by patients and by healthcare providers in the hospital.

Cautionary Statement Regarding Forward Looking Statements

DexCom is a medical device company with a limited operating history. Successful commercialization of the company's products is subject to numerous risks and uncertainties, including a lack of acceptance in the marketplace by physicians and patients, the inability to manufacture products in commercial quantities at an acceptable cost, possible delays in the company's development programs, the inability of patients to receive reimbursement from third-party payors and inadequate financial and other resources. Certain of these risks and uncertainties, in addition to other risks, are more fully described in the company's annual report on Form 10-K for the year ended December 31, 2014, as filed with the Securities and Exchange Commission on February 25, 2015.

Contacts

DexCom, Inc.
Steven R. Pacelli
Executive Vice President, Strategy and Corporate Development
858-200-0200

Release Summary

DexCom Announces Upcoming Conference Presentations

Contacts

DexCom, Inc.
Steven R. Pacelli
Executive Vice President, Strategy and Corporate Development
858-200-0200